You are here: Industry Insights > Mundipharma

News List

Mundipharma to bring cold-fighting product to Africa, ME biospectrumasia
January 23, 2019
BETADINE Cold Defence Nasal Spray is a natural product with anti-viral effects that helps to eliminate 99% of cold and flu viruses and shorten the duration of common colds.
Mundipharma to Bring World's First Gene Therapy for Osteoarthritis to Nine More Countries in APAC firstwordpharma
January 17, 2019
According to the World Health Organisation, osteoarthritis is the single most common cause of disability in older people with an estimated 10%-15% of all people over 60 suffering from it. Currently, its prevalence is increasing.
Mundipharma to Bring World's First Gene Therapy for Osteoarthritis to Nine More Countries in APAC firstwordpharma
January 17, 2019
According to the World Health Organisation, osteoarthritis is the single most common cause of disability in older people with an estimated 10%-15% of all people over 60 suffering from it. Currently, its prevalence is increasing.
Mundipharma applies for marketing Remimazolam in Japan biospectrumasia
December 24, 2018
Mundipharma has submitted an application to the Japanese Pharmaceuticals and Medical Devices Agency to market Remimazolam for general anesthesia in Japan.
Mundipharma to distribute Norspan in Japan expressbpd
December 12, 2018
Norspan is indicated for the relief of chronic pain associated with osteoarthritis and lower back pain
Raman Singh wins Global Executive of the Year Scrip award biospectrumasia
December 03, 2018
Mundipharma CEO, Raman Singh, has won Executive of the Year for small cap & private pharma companies at the annual scrip Awards, which were held in London on 28 November.
EC approves Mundipharma’s Pelmeg to treat febrile neutropenia pharmaceutical-technology
November 27, 2018
The Mundipharma network of independent associated companies has received European Commission (EC) approval for the use of Pelmeg (pegfilgrastim) for treatment of febrile neutropenia in adult cancer patients.
Deals this week: Mundipharma, Ligand Pharmaceuticals pharmaceutical-technology
November 25, 2018
Kolon Life Sciences dosed the first patient in a Phase III trial for Invossa this month. It is hoping to be granted the US Food and Drug Administration’s (FDA) Disease Modifying Osteoarthritis Drug (DMOAD) label.
Working Life: Philippe Bastide, Head of Biosimilars, Mundipharma pharmafile
November 22, 2018
“Don’t conform to what people want – take risks. The people who make a big difference are the ones who take risks in uncertain times”
Mundipharma to bring world's first gene therapy for knee osteoarthritis .biospectrumasia
November 20, 2018
Mundipharma will be responsible for the development, marketing and distribution of Invossa to medical professionals and

Previous page 1 2 3 4 5 6 Next page